Lakewood-Amedex Biotherapeutics Inc. is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials called Bisphosphocins to treat infectious diseases and combat antibiotic-resistant bacterial strains such as MRSA and VRE. The company's approach involves administering Bisphosphocins directly to infection sites, where they rapidly disrupt microbial cell membranes, leading to bacterial and fungal eradication within minutes. Lakewood-Amedex is advancing a gel formulation of Bisphosphocin Nu-3 into Phase 2 clinical trials for treating infected diabetic foot ulcers, while also developing treatments for bladder infections via catheter instillation and lung infections via inhalation. The company focuses on indications suitable for locally acting antimicrobials, positioning itself in the infectious disease and antimicrobial resistance markets. Based in Sarasota, Florida, Lakewood-Amedex Biotherapeutics began trading on the Nasdaq Capital Market in April 2026.